Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).

MLA

Iwama, Eiji, et al. “Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 12, no. 7, July 2017, pp. 1161–66. EBSCOhost, https://doi.org/10.1016/j.jtho.2017.02.012.

APA

Iwama, E., Goto, Y., Murakami, H., Harada, T., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., Bessho, A., Ono, M., Okazaki, A., Akamatsu, H., Morinaga, R., Ushijima, S., Shimose, T., Tokunaga, S., Hamada, A., … Okamoto, I. (2017). Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401). Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 12(7), 1161–1166. https://doi.org/10.1016/j.jtho.2017.02.012

Chicago

Iwama, Eiji, Yasushi Goto, Haruyasu Murakami, Taishi Harada, Shinsuke Tsumura, Hiroyuki Sakashita, Yoshiaki Mori, et al. 2017. “Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 12 (7): 1161–66. doi:10.1016/j.jtho.2017.02.012.